TCS 3,604.45 -47.20 (-1.29%) HDFCBANK 1,828.50 +3.25 (0.18%) 
HINDUNILVR 2,259.35 +22.60 (1.01%) INFY 1,570.40 -33.15 (-2.07%) HDFC 2,729.95 -17.05 (-0.62%) BHARTIARTL 1,730.95 +7.60 (0.44%) KOTAKBANK 2,171.30 +40.15 (1.88%) ICICIBANK 1,348.40 +11.65 (0.87%) ITC 409.80 +0.40 (0.10%) BAJFINANCE 8,948.75 -37.25 (-0.41%) MARUTI 11,521.45 -200.20 (-1.71%) HCLTECH 1,590.95 -35.85 (-2.20%) SBIN 771.60 -0.80 (-0.10%) NESTLEIND 2,251.05 +10.90 (0.49%) ASIANPAINT 2,337.70 -0.50 (-0.02%) WIPRO 262.10 -9.95 (-3.66%) DMART 4,078.15 +13.30 (0.33%) AXISBANK 1,101.90 +3.40 (0.31%) LT 3,491.00 -12.30 (-0.35%) HDFCLIFE 685.55 +3.40 (0.50%) SUNPHARMA 1,735.45 +4.25 (0.25%) ULTRACEMCO 11,504.50 -84.00 (-0.72%) ONGC 246.40 +4.20 (1.73%) BAJAJFINSV 2,005.95 +0.55 (0.03%) BPCL 278.45 +2.50 (0.91%) POWERGRID 290.45 -4.45 (-1.51%) TITAN 3,063.80 -21.85 (-0.71%) BRITANNIA 4,936.90 +98.75 (2.04%) NTPC 357.65 -3.15 (-0.87%) Download Unicorn Signals App
By EquityPandit
A generic insomnia drug, Zolpidem Sublingual tablets has been launche by the drug major Lupin in the US market with 180 days of marketing exclusivity.
GAVIS Pharmaceuticals’ Zolpidem Sublingual tablets has been launched by Lupin Pharmaceuticals after having received final approval from the United States Food and Drug Administration (FDA) as well as from the FTC with 180 days of exclusivity.
